Genentech's Tecentriq meets PFS endpoint in Phase III for first-line RCC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said 1,200 mg IV Tecentriq atezolizumab (MPDL3280A, RG7446) plus Avastin bevacizumab every three weeks as first-line treatment met the co-primary endpoint of improving progression-free survival (PFS) in patients whose tumors expressed PD-L1 vs. Sutent sunitinib in the Phase III IMmotion151 to treat renal cell carcinoma (RCC). The trial enrolled 915 patients with inoperable, locally advanced or metastatic RCC who have not received prior systemic active or experimental therapy.

Data from the trial will presented at an oncology meeting next year. Data for the co-primary endpoint of overall survival (OS) in the intent-to-treat (ITT) population are not yet mature. Genentech said it will discuss the data with regulatory agencies worldwide, including FDA and EMA...